O
NTRA icon

OrbiMed’s Natera NTRA Stock Holding History

OrbiMed’s Portfolio NTRA Stock Details NTRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150,000
Closed -$5.32K – 141
2022
Q2 		$5.32K Hold
150,000
– – 0.1% 111
2022
Q1 		$6.1M Buy
+150,000
New +$9.01M 0.1% 114

Other funds holding NTRA

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OrbiMed's NTRA Position: Q1 2026 in Review

OrbiMed reduced its Natera (NTRA) stake by 28% in Q1 2026, selling an estimated $22.3M and leaving 262,000 shares worth $52.4M. The position accounts for 1.04% of the portfolio, ranked #30.

OrbiMed first reported a position in NTRA in Q3 2015 and has held it in 43 quarters since. The position peaked at $234M in Q2 2021. 762 funds tracked by Wall St. Rank hold NTRA as of Q1 2026.

  • OrbiMed held 262,000 shares of Natera worth $52.4M as of Q1 2026.
  • OrbiMed sold 103,800 Natera shares in Q1 2026, an estimated $22.3M.
  • Natera made up 1.04% of OrbiMed's portfolio in Q1 2026, its #30 holding.
  • OrbiMed first reported a position in Natera in Q3 2015 and has held it in 43 quarters since.
  • OrbiMed's Natera position peaked at $234M in Q2 2021.
  • 762 funds tracked by Wall St. Rank held Natera as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.